The Ascent of Abbott: Humira Marketer Battles With FDA Over Biosimilars
This article was originally published in RPM Report
Executive Summary
Abbott Labs wasn’t considered a serious biologics manufacturer when the biosimilars pathway was first being debated. But with the arthritis treatment Humira now the world’s best-selling pharmaceutical brand, the company has assumed a leadership position just as the biosimilar opportunity is emerging. And what better way to use that new role than by launching an offensive strike against FDA?